{'fraction_non_alphanumeric': 0.03201970443349754, 'fraction_numerical': 0.003694581280788177, 'mean_word_length': 5.948717948717949, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The in-vitro-effects of loxaglate (Hexabrix) on coagulation, fibrinolysis and complement system (author's transl)].

Ioxaglate causes a dose dependent prolongation of thrombin time, thrombin coagulase time, partial thromboplastin time and calcium thromboplastin time. A substantial activation of fibrinolysis, assayed by a dose dependent decrease of plasminogen concentrations, does not take place. Higher concentration of ioxaglate (more than 25 mg iodine/ml) cause a complement activation. No C-3 split products could be detected by two-dimensional immunoelectrophoresis. Ioxaglate induced changes of global coagulation tests are interpreted as being caused by interference of fibrin polymerization. The demonstration of complement activation by high concentrations of ioxaglate has no practical consequences.